AI Article Synopsis
- A study involving 389 older diabetes patients aimed to identify factors that contribute to severe hypoglycemia (low blood sugar levels).
- Out of these patients, 33 (or 8.5%) experienced at least one instance of severe hypoglycemia during the study period.
- The analysis found that taking statins (a type of cholesterol medication) was linked to a lower risk of severe hypoglycemia, while insulin usage was associated with a higher risk.
Article Abstract
Three hundred and eighty-nine older patients with diabetes attending an ambulatory diabetes center were included to determine risk factors of severe hypoglycemia (SH). Thirty-three (8.5%) patients had at least one severe hypoglycemia. In multivariate analyze, statin was associated with lower risk and insulin was associated with higher risk of SH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diabres.2020.108034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Time Below Range and Its Influence on Hypoglycemia Awareness and Severe Hypoglycemia: Insights From the Association of British Clinical Diabetologists Study.
Diabetes Care
January 2025
Allam Diabetes Centre, Hull University Teaching Hospitals National Health Service (NHS) Trust, Hull, U.K.
Objective: This study aimed to explore the relationship between time below range (TBR), impaired awareness of hypoglycemia (IAH), and severe hypoglycemia (SH).
Research Design And Methods: This cross-sectional study analyzed data from individuals with diabetes using continuous glucose monitors (CGMs) in the Association of British Clinical Diabetologists audit. Hypoglycemia awareness was assessed via the Gold score (≥4 denoting IAH), and SH was defined as hypoglycemia requiring third-party assistance.
Strategies to Enhance the Therapeutic Efficacy of GLP-1 Receptor Agonists through Structural Modification and Carrier Delivery.
Chembiochem
January 2025
Nankai University, Institute of Polymer Chemistry, CHINA.
Article Synopsis
- Diabetes is a condition where the body either doesn't produce enough insulin or can't effectively use it, leading to high blood sugar levels.
- Recently, GLP-1 receptor agonists (GLP-1RAs) have gained popularity for treating type 2 diabetes due to their ability to manage blood sugar, lower the risk of low blood sugar, and aid in weight loss.
- Despite their benefits, GLP-1RAs have issues like instability and breakdown by enzymes, prompting research into methods like structural modifications and delivery systems to enhance their effectiveness and usability.
Managing Hypoglycaemia in Patients With Insulinoma-A Tertiary Centre Experience and Review of the Literature.
Clin Endocrinol (Oxf)
December 2024
Department of Diabetes and Endocrinology, Cambridge Cancer Centre and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
The management of hypoglycaemia is pivotal in the care of patients with insulinoma. Blood glucose monitoring and regulation needs careful attention pre- and peri-operatively for patients undergoing surgical resection and as part of the long-term management for patients with inoperable or metastatic disease. Hypoglycaemia symptoms are frequently pervasive and disabling, with many patients showing impaired hypoglycaemia awareness that can lead to life-threatening severe hypoglycaemia.
View Article and Find Full Text PDFA Six-Month Prospective Audit of Hypoglycemia in Non-Critically Ill Inpatients at a Tertiary Care Hospital in North India: Prevalence, Presentation, and Prevention.
Cureus
November 2024
Medicine, SGT Medical College, Hospital and Research Institute, Gurugram, IND.
Objective: This research aimed to assess the prevalence, presentation, and risk factors associated with hypoglycemia in non-critically ill vs. critically ill inpatients at a tertiary care hospital in North India, focusing on identifying differences in clinical parameters and outcomes between these two patient populations over six months.
Methodology: This six-month prospective study, conducted at a tertiary care hospital in North India, evaluated the frequency, presentation, and prevention of hypoglycemia in 200 hospitalized patients, evenly divided between non-critically ill and critically ill groups.
Insulin Degludec in Critically Ill Patients with Type 2 Diabetes Mellitus: A Prospective Interventional Study.
Endocr Pract
December 2024
Department of Medicine, McMaster University, 1280 Main St W, Hamilton, Ontario L8S 4L8, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main St W, Hamilton, Ontario L8S 4L8, Canada. Electronic address:
Objective: Dysglycemia has deleterious outcomes on critically ill patients with diabetes mellitus (DM). Insulin degludec, an ultra-long-acting insulin, is associated with lower rates of hypoglycemia and blood glucose (BG) variability in non-critically ill patients. The experience with insulin degludec in the intensive care units is lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!